COVID-19 vaccine immunological studies in Finland

Conditions

COVID-19 infection

Brief summary

Proportion of seropositive subjects with an antibody level above the target level in groups of vaccine recipients receiving different vaccine products at 6 months after two doses against the prevailing virus variant

Detailed description

Antibody and neutralising antibody levels and percentages of those above the target: in the group receiving combinations of different vaccine products,in a group of people who received the vaccine at different dose intervals (e.g. 3 weeks, 8 weeks, 12 weeks), in the group receiving different numbers of vaccine doses , in the COVID19-infected group, in different age groups, in groups at risk of COVID-19 and in immunocompromised groups, against different virus variants, Cell-mediated immune responses, Response variables regarding immunity studies against other microbes will be developed according to the epidemic situation

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGComirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

DRUGComirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

DRUGCOVID-19

DRUGVIRAL VECTOR

DRUGNON-REPLICATING

DRUGSpikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine

DRUGComirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

DRUGNuvaxovid dispersion for injection COVID-19 Vaccine (recombinant

DRUGadjuvanted)

DRUGSpikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

DRUGComirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection COVID-19 mRNA Vaccine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Antibody and neutralising antibody levels and percentages of those above the target: in the group receiving combinations of different vaccine products,in a group of people who received the vaccine at different dose intervals (e.g. 3 weeks, 8 weeks, 12 weeks), in the group receiving different numbers of vaccine doses , in the COVID19-infected group, in different age groups, in groups at risk of COVID-19 and in immunocompromised groups, against different virus variants, Cell-mediated immune responses, Response variables regarding immunity studies against other microbes will be developed according to the epidemic situation	—

Measure

Time frame

Antibody and neutralising antibody levels and percentages of those above the target: in the group receiving combinations of different vaccine products,in a group of people who received the vaccine at different dose intervals (e.g. 3 weeks, 8 weeks, 12 weeks), in the group receiving different numbers of vaccine doses , in the COVID19-infected group, in different age groups, in groups at risk of COVID-19 and in immunocompromised groups, against different virus variants, Cell-mediated immune responses, Response variables regarding immunity studies against other microbes will be developed according to the epidemic situation

—

Primary

Measure	Time frame
Proportion of seropositive subjects with an antibody level above the target level in groups of vaccine recipients receiving different vaccine products at 6 months after two doses against the prevailing virus variant	—

Countries

Finland

Outcome results

None listed